FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 15:45:13 2024-06-17 EDT | ||
| 5.97 EUR | +6.80% |
|
| Current month | -19.00% | ||
| 1 month | -29.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 5.97 | +6.80% |
| 24-06-14 | 5.59 | -2.10% |
| 24-06-13 | 5.71 | -3.22% |
| 24-06-12 | 5.9 | +6.12% |
| 24-06-11 | 5.56 | +3.73% |
Real-time BOERSE MUENCHEN
Last update June 17, 2024 at 03:45 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33LG |
| ISIN | DE000HD33LG9 |
| Date issued | 2024-02-27 |
| Strike | 577 $ |
| Maturity | Unlimited |
| Parity | 17.07 : 1 |
| Emission price | 10.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.3 € |
|---|---|
| Lowest since issue | 5.25 € |
| Spread | 0.02 € |
| Spread % | 0.33% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Certificates
- Certificat
